MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
underwritten public...
$324,300K
Proceeds from exercise of
employee stock options
$4,522K
Net cash provided by
financing activities
$328,335K
Canceled cashflow
$487K
Net decrease in
cash, cash...
$29,969K
Canceled cashflow
$298,366K
Payment of offering
costs
$487K
Proceeds from maturities
of marketable...
$72,868K
Collaboration receivable
-$7,000K
Stock-based compensation
expense
$5,949K
Accounts payable
$4,377K
Depreciation
$2,029K
Defined benefit plan
liability
-$49K
Net cash used in
investing activities
-$260,997K
Net cash used in
operating activities
-$37,369K
Canceled cashflow
$72,868K
Canceled cashflow
$19,404K
Purchases of marketable
securities
$331,997K
Net loss
-$44,503K
Purchases of property and
equipment
$1,868K
Deferred revenue
-$4,209K
Accrued expenses and
other current...
-$3,712K
Prepaid expenses and
other assets
$2,921K
Net accretion of
discounts/premiums on marketable...
-$985K
Right-of-use assets and
operating lease...
-$434K
Other receivables
$9K
Back
Back
Cash Flow
source: myfinsight.com
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)